DEA Places Four Synthetic Cannabinoids in Schedule I
The Drug Enforcement Administration has placed four synthetic cannabinoids into Schedule I due to their high abuse potential and lack of accepted medical use. These DEA Schedule I synthetic cannabinoids include 4F-MDMB-BUTICA, ADB-4en-PINACA,…
Tennessee THC Ban Impact on Cannabis Patients and Clinicians
Tennessee's July 1 THC ban prohibits THCA products exceeding 0.3% THC and restricts THCV, closing legal loopholes for hemp-derived cannabinoids. The Tennessee THC ban significantly impacts patients who previously used these products therapeutically and…
DEA Places Synthetic Cannabinoid CUMYL-PEGACLONE in Schedule I
The U.S. Drug Enforcement Administration has placed CUMYL-PEGACLONE, a synthetic cannabinoid analog, into Schedule I of the Controlled Substances Act due to its high abuse potential and lack of accepted medical use. This CUMYL-PEGACLONE Schedule I…
Texas Hemp Ban Enforceable During Legal Challenge Court Rules
A Texas court ruled the state's Total THC hemp regulations remain enforceable during ongoing legal challenges, creating immediate uncertainty for patient access to cannabinoid products. The Texas hemp ban enforceable decision means products compliant…
Black Market Cannabis Products Pose Clinical Safety Risks for Patients
Black market cannabis products with doubled THC concentrations and novel cannabinoid combinations pose significant safety risks for patients seeking therapeutic alternatives. These unregulated formulations lack quality control, potency verification, and…
Absolute Cinema
/* Suppress TOC widgets */ #ez-toc-container, .ez-toc-wrap, .ez-toc-v2_0, div.ez-toc-v2_0, div#ez-toc-container { display: none !important; visibility: hidden !important; height: 0 !important; opacity: 0 !important; } /* Constrain oversized headline…
Y’all Got Any More Of That
/* Suppress TOC widgets */ #ez-toc-container, .ez-toc-wrap, .ez-toc-v2_0, div.ez-toc-v2_0, div#ez-toc-container { display: none !important; visibility: hidden !important; height: 0 !important; opacity: 0 !important; } /* Constrain oversized headline…
Medical Cannabis Clinical Trials For Pain Announced In Germany
/* Suppress TOC widgets */ #ez-toc-container, .ez-toc-wrap, .ez-toc-v2_0, div.ez-toc-v2_0, div#ez-toc-container { display: none !important; visibility: hidden !important; height: 0 !important; opacity: 0 !important; } /* Constrain oversized headline…
May Recap: New AWS Privileged Permissions and Services – Security Boulevard
/* Suppress TOC widgets */ #ez-toc-container, .ez-toc-wrap, .ez-toc-v2_0, div.ez-toc-v2_0, div#ez-toc-container { display: none !important; visibility: hidden !important; height: 0 !important; opacity: 0 !important; } /* Constrain oversized headline…
DEA Synthetic Cannabinoids Schedule I Placement Updates 2026
This Policy Watch covers DEA synthetic cannabinoids schedule I placement updates for June 08, 2026. These regulatory actions affect clinical and research practices involving controlled substances. Clinicians should stay informed about these changes to…
